drugset / Trial / NCT06007924
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects. Funding Source- FDA OOPD.
Timeline
- Start
- 2023-08-16
- Primary completion
- 2027-08-16
- Completion
- 2027-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | 3.2 mg | — |
| Subject | Defactinib | Small molecule | 200 mg | — |